USPTO Examiner HEASLEY MEGHAN CHRISTINE - Art Unit 1626

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19042986MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASESJanuary 2025April 2025Allow300YesNo
19020776CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTATJanuary 2025March 2025Allow200YesNo
18868756C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCERNovember 2024April 2025Allow510YesNo
18768367BENZOPYRIMIDINE COMPOUNDS AND USE THEREOFJuly 2024January 2025Allow710YesNo
18743634HETEROARYL AZOLE COMPOUND AND PEST CONTROL AGENTJune 2024February 2025Allow800NoNo
18679720FORMS OF ATICAPRANTMay 2024August 2024Allow200YesNo
186502073-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOFApril 2024July 2024Allow300YesNo
18589841HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDERFebruary 2024May 2024Allow200YesNo
18443959COMPOUND OR SALT THEREOF AND LIPID PARTICLESFebruary 2024March 2025Allow1300YesNo
18440166SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOFFebruary 2024April 2025Allow1421YesNo
18413842ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOFJanuary 2024January 2025Allow1221YesNo
18395130PYRAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow300YesNo
18571452Cancer TreatmentDecember 2023March 2025Allow1511YesNo
18315526COMPOUNDS AND USES THEREOFMay 2023July 2024Allow1411YesNo
18304202SYNTHESIS OF NIROGACESTATApril 2023January 2025Allow2131YesNo
180291773-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOFMarch 2023January 2025Allow2200YesNo
18191247ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERSMarch 2023March 2024Allow1211NoNo
18119776REHYDRATION COMPOSITION AND METHOD OF USEMarch 2023April 2025Allow2540YesNo
18178961FORMS OF ATICAPRANTMarch 2023August 2023Allow600YesNo
18115058BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATIONFebruary 2023October 2024Abandon1920NoNo
18171831USES OF BUPIVACAINE MULTIVESICULAR LIPOSOMES AS STELLATE GANGLION BLOCKFebruary 2023June 2025Allow2831YesNo
18169016CRYSTALLINE PROSTACYCLIN (IP) RECEPTOR AGONIST AND USES THEREOFFebruary 2023May 2024Allow1510NoNo
18169155METHODS OF ADMINISTERING CANNABINOIDSFebruary 2023June 2025Allow2841YesYes
18162205APPLICATION OF DIPYRRINATO-IRIDIUM COMPLEXES IN ANTI-TUMOR AND ANTI-BACTERIAL THERAPYJanuary 2023August 2024Allow1910NoNo
18162365IRAK DEGRADERS AND USES THEREOFJanuary 2023May 2024Allow1510NoNo
18162092INTRAVENEOUS DOFETILIDE TO REDUCE THE RISK OF DEVELOPING AF/AFL POST CORONARY BYPASS SURGERYJanuary 2023March 2025Allow2520YesYes
18160866STABLE PHARMACEUTICAL COMPOSITION OF TOPIRAMATEJanuary 2023February 2024Abandon1310NoNo
18100754SQUALAMINE CRYSTALLINE POLYMORPHSJanuary 2023July 2024Abandon1811NoNo
18090024STABLE PHARMACEUTICAL COMPOSITION OF NIMODIPINEDecember 2022March 2024Abandon1510NoNo
18068857BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTSDecember 2022April 2024Allow1610YesNo
18002080SMALL MOLECULE MODULATORS OF IL-17December 2022June 2025Allow3000YesNo
18064080BICYCLIC AMINES AS CDK2 INHIBITORSDecember 2022December 2023Allow1301NoNo
18078785STAT3 DEGRADERS AND USES THEREOFDecember 2022October 2024Abandon2221YesNo
18060108Methods To Treat Cancer With AMXT 1501 and DFMONovember 2022April 2025Abandon2830YesNo
18055146TREATMENT FOR EPILEPTIC SEIZURESNovember 2022April 2024Abandon1711NoNo
17962714Methods Of Treating Multiple SclerosisOctober 2022March 2025Allow2931YesNo
17951696TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED CANCERS BY PD-L1 INHIBITORSSeptember 2022February 2024Abandon1610NoNo
17939703USE OF CANNABINOID COMPOUNDS TO TREAT OR PREVENT FUNGAL GROWTH OF C. ALBICANSSeptember 2022January 2024Abandon1601NoNo
17929320RESVERATROL COMPOSITION, PREPARATION METHOD AND APPLICATION THEREOFSeptember 2022August 2024Abandon2321NoNo
17795516MULTI-TARGET TYROSINE KINASE INHIBITORJuly 2022June 2025Allow3500YesNo
17854591PROCESS FOR PREPARING NITRILE INTERMEDIATES FOR NITROGEN-CONTAINING CHELATORSJune 2022January 2024Abandon1801NoNo
17786792COMPOUND MODULATORS OF STINGJune 2022May 2025Allow3500YesNo
17785239SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICSJune 2022January 2025Allow3210YesNo
17825260COMPOSITION OF ACYLETHANOLAMIDES FROM OLIVE OIL FATTY ACIDSMay 2022May 2024Allow2411NoNo
17756545FUSED PYRIDINE RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOFMay 2022April 2025Allow3500YesNo
17732717PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAMEApril 2022May 2025Allow3700YesNo
17769389FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND MANUFACTURING METHOD FOR SAMEApril 2022April 2025Allow3600YesNo
17761014METHODS AND COMPOSITIONS FOR TREATING PAIN AND OTHER EPH RECEPTOR-ASSOCIATED CONDITIONSMarch 2022June 2025Abandon3901NoNo
17686556CYCLE WATER TREATMENT PROCESS FOR ETHLYENE EPOXIDATIONMarch 2022November 2023Allow2010NoNo
17632065HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTSFebruary 2022February 2025Allow3700YesNo
17292690USE OF 3-O-SULFAMOYLOXY-7Beta-METHYL-D-HOMO-6-OXAESTRA-1,3,5(10),8(9)-TETRAEN-17A-ONE TO TREAT BREAST CANCERJanuary 2022September 2024Allow4000YesNo
17584577HEXASUBSTITUTED BENZENES, SURFACES MODIFIED THEREWITH, AND ASSOCIATED METHODSJanuary 2022February 2025Allow3700YesNo
17624182IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND APPLICATIONDecember 2021April 2025Abandon3901NoNo
17554792BIOORTHOGONAL COMPOSITIONSDecember 2021February 2025Allow3831YesNo
17614941BENZOTRIAZOLE DERIVATIVENovember 2021January 2025Allow3800YesNo
17610031METFORMIN COMPLEXES WITH TRANSITION METALS AND P GROUP ELEMENTSNovember 2021February 2025Allow3931YesNo
17609874BCL-2 INHIBITORS FOR USE IN THE TREATMENT OF A BCL-2 MEDIATED CANCER CARRYING THE GLY101VAL MUTATIONNovember 2021March 2025Abandon4001NoNo
17599806AZAAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCEROctober 2021November 2024Allow3801YesNo
17442173Prophylactic or Therapeutic Agent for CancerSeptember 2021March 2025Allow4211YesNo
17442064SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOFSeptember 2021October 2024Allow3700NoNo
17440872INDAZOLES AS LRRK2 INHIBITORSSeptember 2021February 2025Abandon4101NoNo
17477924METHODS OF TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTERATED DEXTROMETHORPHAN AND QUINIDINESeptember 2021March 2025Abandon4201NoNo
17430312Agent for Eliminating Pluripotent Stem CellsAugust 2021January 2025Abandon4101NoNo
17392036BENZOTHIAZOLE AND RELATED COMPOUNDSAugust 2021April 2025Allow4401YesNo
17376963APOPTOSIS-INDUCING AGENTSJuly 2021January 2025Allow4210YesNo
17311627HETEROCYCLIC COMIPOUND AS CDK-HDAC DUAL PATHWAY INHIBITORJune 2021March 2025Allow4511YesNo
17309494Heterocyclic Compound as CDK-HDAC Double-Channel InhibitorJune 2021March 2025Allow4611YesNo
17332687COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERSMay 2021June 2025Abandon4921YesNo
17297198NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOFMay 2021September 2024Allow4011NoNo
17295181Methods of Treating Acute HCVMay 2021December 2024Abandon4310NoNo
17289761NEW TETRAHYDROPYRIMIDODIAZEPIN AND TETRAHYDROPYRIDODIAZEPIN COMPOUNDS FOR TREATING PAIN AND PAIN RELATED CONDITIONSApril 2021September 2024Abandon4001NoNo
17289963METHOD OF ENHANCING IMMUNE-BASED THERAPYApril 2021March 2025Abandon4711NoNo
17290150DRUG COMPOSITIONSApril 2021December 2024Abandon4401NoNo
17289786READY TO USE INTRAVENOUS INFUSION OF BRIVARACETAM OR SALT THEREOFApril 2021March 2025Abandon4711YesNo
17289913USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCERApril 2021November 2024Abandon4301NoNo
17290045RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOFApril 2021January 2025Allow4511NoNo
172897943-(1,2,3,6-TETRAHYDROPYRIDIN-2-YL) PYRIDINE GLUTARATE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOFApril 2021December 2024Allow4411YesNo
17289008A LIQUID INJECTABLE COMPOSITIONApril 2021May 2025Allow4831YesNo
17288721CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITORApril 2021February 2025Abandon4621NoNo
17287548NEW ANTHELMINTIC COMPOUNDSApril 2021February 2025Allow4521YesNo
17287356FEED ADDITIVE FOR CATTLE COMPRISING N-ACETYL-L-TRYPTOPHAN AS ACTIVE INGREDIENTApril 2021August 2024Allow4020NoNo
17286818INDANE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORSApril 2021April 2024Allow3610NoNo
17286693BETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORSApril 2021July 2024Allow3910YesNo
17285653Co-Crystals Comprising Levothyroxine And A Dicarboxylic AcidApril 2021March 2024Allow3501YesNo
17281251PD-L1 ANTAGONIST COMPOUNDMarch 2021June 2024Allow3811YesNo
17281481OXIDE CATALYST AND METHOD FOR PRODUCING UNSATURATED NITRILEMarch 2021March 2025Allow4821YesNo
17206044USE OF A CATHEPSIN S INHIBITOR AGAINST THE FORMATION OF ANTI-DRUG ANTIBODIESMarch 2021May 2025Allow5021YesNo
17277562PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASEMarch 2021September 2024Allow4221YesNo
17200743TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USEMarch 2021April 2024Abandon3710NoNo
17185206CRYSTALLINE FORMS OF AN NK-1 ANTAGONISTFebruary 2021April 2024Allow3810NoNo
17271531HETEROARYL AZOLE COMPOUND AND PEST CONTROL AGENTFebruary 2021August 2024Allow4211NoNo
17271424CRYSTAL OF PYRAZOLO[3,4-D]PYRIMIDINEFebruary 2021June 2024Allow3910NoNo
17269577CAPSAICIN SEQUENTIAL DOSING METHOD FOR TREATMENT OF KNEE JOINT PAINFebruary 2021November 2024Abandon4520NoNo
17269811SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVESFebruary 2021June 2024Allow4011YesNo
17269725N-SUBSTITUTED-1H-1,2,4-TRIAZOLE-3-CARBOXAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAMEFebruary 2021April 2024Allow3810NoNo
17266474PRMT5 INHIBITORSFebruary 2021October 2023Allow3200NoNo
17266075Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations ThereofFebruary 2021August 2024Allow4211YesNo
17266026CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORSFebruary 2021May 2024Allow3910YesNo
17264744HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCERJanuary 2021April 2024Allow3801NoNo
17263913COMBINATION THERAPY FOR TREATING CANCERJanuary 2021April 2024Abandon3901NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HEASLEY, MEGHAN CHRISTINE.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
1
(33.3%)
Not Allowed After Appeal Filing
2
(66.7%)
Filing Benefit Percentile
47.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HEASLEY, MEGHAN CHRISTINE - Prosecution Strategy Guide

Executive Summary

Examiner HEASLEY, MEGHAN CHRISTINE works in Art Unit 1626 and has examined 102 patent applications in our dataset. With an allowance rate of 68.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner HEASLEY, MEGHAN CHRISTINE's allowance rate of 68.6% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HEASLEY, MEGHAN CHRISTINE receive 1.03 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HEASLEY, MEGHAN CHRISTINE is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +47.1% benefit to allowance rate for applications examined by HEASLEY, MEGHAN CHRISTINE. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 42.0% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 36.4% of cases where such amendments are filed. This entry rate is in the 47% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 87.5% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.